Genext Genomics Profile
Key Indicators
- Authorised Capital ₹ 3.00 M
as on 07-07-2024
- Paid Up Capital ₹ 3.00 M
as on 07-07-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 4.12%
(FY 2020)
- Profit 2.68%
(FY 2020)
- Ebitda 7.00%
(FY 2020)
- Net Worth -4.76%
(FY 2020)
- Total Assets 55.67%
(FY 2020)
About Genext Genomics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 M and a paid-up capital of Rs 3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Ravi Kashikar, Manjiri Singh, Ashwin Kashikar, and Two other members serve as directors at the Company.
- CIN/LLPIN
U73100MH2011PTC212683
- Company No.
212683
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jan 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Genext Genomics Private Limited offer?
Genext Genomics Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, Corona Test Kit.
Who are the key members and board of directors at Genext Genomics?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashwin Kashikar  | Director | 24-Jan-2011 | Current |
| Ravi Kashikar | Director | 24-Jan-2011 | Current |
| Manjiri Singh | Director | 24-Jan-2011 | Current |
| Shivali Kashikar | Director | 24-Jan-2011 | Current |
| Supriya Kashikar | Whole-Time Director | 16-Feb-2018 | Current |
Financial Performance of Genext Genomics.
Genext Genomics Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 4.12% increase. The company also saw a slight improvement in profitability, with a 2.68% increase in profit. The company's net worth dipped by a decrease of 4.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genext Genomics?
In 2020, Genext Genomics had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dharti Farming And Cultivation Private LimitedActive 27 years 2 monthsManjiri Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Genext Genomics?
Unlock and access historical data on people associated with Genext Genomics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genext Genomics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genext Genomics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
